Liposomes as Potential Carrier System for Targeted Delivery of Polyene Antibiotics
Liposomes as Potential Carrier System for Targeted Delivery of Polyene Antibiotics
复制标题
DOI：
10.2174/1872213x113079990016
复制
发表时间：
2013-01-01
影响因子：
4.2
通讯作者：
Wala, Santosh M.
中科院分区：
文献类型：
--
作者：
Naik, Suresh R.;Desai, Sandhya K.;Wala, Santosh M.
新治疗方式的开发涉及药物载体的使用，例如脂质体，它可以改变药物的药代动力学和生物分布。将多烯抗生素掺入脂质体主要通过循环单核细胞/巨噬细胞吞噬脂质体并运输至感染部位来改善其在部位的可用性、生物分布和治疗指数。多烯抗生素（AmB、SJA-95、HA-1-92）和其他抗生素（链霉素、妥布霉素、喹诺酮类、抗结核和抗癌药物）、脂质体制剂从治疗效果和毒性的角度描述了可能具有的优势。多烯大环内酯类抗生素脂质体制剂被证明对治疗系统性真菌病更为有效。 AmB-环糊精衍生物包合物可转化为脂质体的水相，是脂质体制备的重大突破。脂质体药物掺入制剂已成为将现有多烯类抗生素开发为临床医学有用化疗药物的重要研究领域之一。近年来，其他抗生素也已使用多种材料、磷脂酰乙醇胺衍生物（聚乙二醇化脂质体、酶敏感缀合物、抗癌药物的流体体和抗结核药物的聚乳酸/乙醇酸微球）掺入脂质体中。此外，还尝试扩展受体介导的药物靶向并审查一些相关专利。
The development of new therapeutic modalities involves the use of drug carrier, such as liposomes, which can modify pharmacokinetic and bio-distribution of drug profile. Polyene antibiotics incorporation into liposomes improves its availability at the site, bio-distribution and therapeutic index mainly through the engulfment of liposomes by circulating monocytes/macrophages and transportation to the site of infection. Polyene antibiotics (AmB, SJA-95, HA-1-92) and other antibiotics (streptomycin, tobramycin, quinolones, anti-tubercular and anti-cancer drugs), liposomal preparations are described with possible advantages from therapeutic efficacy and toxicity point of view. The polyene macrolide antibiotics liposomal preparations proved to be more effective in the treatment of systemic mycosis. The AmB-cyclodextrin derivatives inclusion complex is a major breakthrough in liposomal preparation which can be converted into aqueous phase of liposome. Liposomal drug incorporated preparation has been one of the important areas of research for developing the existing polyene antibiotics into useful chemotherapeutic agents in clinical medicine. In recent past other antibiotics have also been incorporated into liposomes using wide variety of materials, phosphatidylethanolamine derivatives (pegylated liposomes, enzyme sensitive conjugates, fluidosomes of anti-cancer drugs and poly lactic/glycolic acid microspheres for anti-tuberculosis drugs). In addition, attempts were also made to extend the receptor mediated drug targeting and to review some relevant patents.